BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29920491)

  • 1. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
    ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
    Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
    Chang H; Samiee S; Yi QL
    Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
    Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
    J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
    Straka C; Knop S; Vogel M; Müller J; Kropff M; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Salwender H; Wandt H; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Fischer T; Liebisch P; Engelhardt M; Einsele H
    Eur J Haematol; 2019 Sep; 103(3):255-267. PubMed ID: 31231828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
    Okura M; Ida N; Yamauchi T
    Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation.
    Wang H; Zhou X; Zhu JW; Ye JN; Guo HF; Sun C
    Oncol Lett; 2018 Nov; 16(5):5655-5666. PubMed ID: 30344721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
    Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
    J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
    Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
    Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of CD117 Expression on Response of Multiple Myeloma Patients to Chemotherapy].
    Tang HL; Shu MM; Dong BX; Gu HT; Liang R; Bai QX; Yang L; Zhang T; Gao GX; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1346-51. PubMed ID: 26524035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma.
    Pozdnyakova O; Morgan EA; Li B; Shahsafaei A; Dorfman DM
    Leuk Lymphoma; 2012 Oct; 53(10):1905-10. PubMed ID: 22423624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
    Leukemia; 2018 Mar; 32(3):712-718. PubMed ID: 28848227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.
    Minoia C; Pisapia G; Palazzo G; Ingrosso C; Buonanno M; Spinosa C; Prudenzano A; Pricolo G; Mazza P
    Bone Marrow Transplant; 2015 Nov; 50(11):1486. PubMed ID: 26281030
    [No Abstract]   [Full Text] [Related]  

  • 18. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
    Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
    Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M
    J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification].
    Hu K; Wang J; Zhu MX; Wang YF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1624-7. PubMed ID: 25543486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.